Financials (USD)
Sales 2024 * | 185M | Sales 2025 * | 251M | Capitalization | 354M |
---|---|---|---|---|---|
Net income 2024 * | -12M | Net income 2025 * | 23M | EV / Sales 2024 * | 1.91 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.41 x |
P/E ratio 2024 * |
-31
x | P/E ratio 2025 * |
16.9
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.41% |
Latest transcript on Imprimis Pharmaceuticals Inc
Managers | Title | Age | Since |
---|---|---|---|
Mark Baum
CEO | Chief Executive Officer | 51 | 05-12-31 |
Andrew Boll
DFI | Director of Finance/CFO | 41 | 11-11-30 |
Jamie Webb
IRC | Investor Relations Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Mark Baum
CEO | Chief Executive Officer | 51 | 05-12-31 |
Director/Board Member | 65 | Jan. 25 | |
Adrienne Graves
BRD | Director/Board Member | 69 | Jan. 25 |
1st Jan change | Capi. | |
---|---|---|
+25.78% | 653B | |
+27.00% | 556B | |
-6.46% | 354B | |
+20.34% | 331B | |
+3.21% | 296B | |
+13.09% | 233B | |
+5.46% | 201B | |
-9.61% | 193B | |
-6.34% | 144B |